|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Multicenter phase Ⅱ study of irinotecan,cisplatin,and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma显示文摘 | Shah MA Ramanathan RK Ilson DH | 2006 | J Clio Oncol2006，24，33： | 1 |
| 2 | Phase Ⅱ study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer显示文摘 | Bao PQ Ramanathan RK Krasinkas A | 2011 | Ann Surg Oncol2011，18，4： | 1 |
| 3 | Gemcitabine plus nab-paelitaxel is an active regimen in patients with advancedpancreatic cancer: a phase I /~ trial显示文摘 | Yon Hoff DD Ramanathan RK Borad M J | 2011 | J Clin Oncol2011，29，34： | 1 |
| 4 | A multicenter phase Ⅱ study of irinotecan (CPT),cisplatin (CIS),and bevacizumab (BEV) in patients with unresectable or metastable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma 显示文摘 | Shah MA Ilson D Ramanathan RK | 2005 | J Clin Onco:2005 ASCO Annual Meeting Proceedings2005，23，16： | 1 |
| 5 | Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study 显示文摘 | Hochster HS Hart LL Ramanathan RK | 2008 | J Clin Oncol2008，26，21： | 1 |
| 6 | A phase Ⅱ study of lapatinib in patients with advanced biliary tree and hepatocellular cancer显示文摘 | Ramanathan RK Belani CP Singh DA | | 0，，04： | 1 |
| 7 | Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors显示文摘 | JUNG LL RAMANATHAN RK EGORIN MJ | 2004 | Cancer Chemother Pharmacol2004，54，6： | 1 |
| 8 | Sensitive liquid chromatography-mass spectrometry assay for quantification of docetaxel and paclitaxel in human plasma显示文摘 | Parise RA Ramanathan RK Zamboni WC | 2003 | J Chromatogr B2003，783，1： | 1 |
| 9 | Combined-Modality treatment of locally advanced non-small cell lung cancer显示文摘 | Belani CP and Ramanathan RK | 1998 | Chest1998，113，1： | 1 |
| 10 | Sensitive liquid chromatography-mass spectrometry assay for quantification of docetaxel and paclitaxel in human plasma显示文摘 | Parise RA Ramanathan RK Zamboni WC | 2003 | Journal of Chromatography B2003，783，1： | 1 |
| 11 | Safety and toxicity analysis of oxalipiatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer显示文摘 | Ramanathan RK Clark JW Kemeny NE | 2003 | J Clin 0ncol2003，21，： | 1 |
| 12 | Safety and toxicity analysis of oxalipiatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer 显示文摘 | Ramanathan RK Clar JW Kemeny NE | 2003 | J Clin Oncol2003，21，： | 1 |
| 13 | Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma显示文摘 | Shah MA Ramanathan RK Ilson DH | 2006 | J Clin Oncol2006，24，33： | 1 |
| 14 | A phase Ⅲ trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer 显示文摘 | Oettle H Richards D Ramanathan RK | | Ann Oncol0，16，10： | 1 |
| 15 | Disposition of 9-nitrocamptothecin and its 9-aminocamptothecinmetabolite in relation to ABC transporter genotypes 显示文摘 | ZAMBONI WC RAMANATHAN RK MCLEOD HL | 2006 | Invest New Drugs2006，24，5： | 1 |
| 16 | Multieenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma显示文摘 | Shah MA Ramanathan RK Ilson DH | 2006 | J Clin Oncol2006，24，33： | 1 |
| 17 | Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastat- ic colorectal cancer: results of the TREE study显示文摘 | Hochster HS Hart LL Ramanathan RK | 2008 | J Clin On- col2008，26，21： | 1 |
| 18 | Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer:results of the TREE Study显示文摘 | Hochster HS Hart LL Ramanathan RK | | 0，，21： | 1 |
| 19 | Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase I b and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gerncitabine plus erlotinib (SWOG S0727)显示文摘 | Philip PA Goldman B Ramanathan RK | 2014 | Cancer2014，120，19： | 1 |
| 20 | Transient pulmonary infiltrates : a hypersensitivi- ty reaction to paclitaxel 显示文摘 | Ramanathan RK Belani CP | 1996 | Ann In- tern Med1996，124，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员